CABG Medical Announces Commencement of Clinical Trials in Europe

MINNEAPOLIS, Sept. 12  /PRNewswire-FirstCall/ -- CABG Medical, Inc. (NASDAQ:CABG) today announced the commencement of enrollment in its European clinical trial of the Holly Graft(TM) System, a drug eluting graft (DEG) for facilitating a coronary artery bypass procedure.  The Company announced that a total of three patients were treated with the Holly Graft System in Hannover, Germany.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO )

"The initiation of our clinical trials in European markets, such as Germany, represents a significant milestone for the Company," said Manny Villafana, Chairman and CEO.  "Additionally, we are very pleased to be collaborating with respected surgeons and cardiac programs throughout the European Union."

The patients were treated by Prof. Dr. Uwe Klima, M.D., a cardiac surgeon at the Medizinische Hochschule Hannover in Hannover, Germany.

"This represents the first step in a true advancement for cardiac surgery and to advance our goal of less invasive procedures for coronary bypass. Additionally, the introduction of drug-eluting technology, represents a new opportunity to improve patients outcomes," Professor Klima commented.  "Time and results will determine the place of the Holly Graft System as a source of conduit."

In keeping with its historical policy on disclosure, CABG does not intend to provide press releases documenting individual human cases going forward. In this case, however, the initiation of human cases in Europe, constitutes a significant development for the Company, thereby warranting a news release to the investment community.

About CABG Medical

CABG Medical, Inc. is a medical technology company developing technologies and therapies to improve the treatment of coronary heart disease by advancing conventional bypass surgery.  We have designed our first product, the Holly Graft(TM) System, by leveraging our understanding of flow dynamics, material sciences and drug combinations to create a drug-eluting graft (DEG) system.

Safe Harbor

This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management.  Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including regulatory actions, competition, and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission. 

http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO

http://photoarchive.ap.org/

DATASOURCE: CABG Medical, Inc.



CONTACT:  Manny Villafana, Chairman & CEO, or John L. Babitt, President &

CFO, both of CABG Medical, Inc., [phone], Fax [phone]

Copyright